Sanofi Completes $3.68-Billion Acquisition of Principia Biopharma

News
Article

The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase inhibitors for its portfolio of next-generation transformative treatments for autoimmune diseases.

Sanofi announced on Sept. 28, 2020 that it has completed its acquisition of Principia Biopharma, a late-stage biopharmaceutical company located in San Francisco, CA, for approximately $3.68 billion.

The acquisition, first announced in Aug. 17, 2020, will give Sanofi access to Principia’s Bruton tyrosine kinase (BTK) inhibitors to add to its portfolio of next-generation transformative treatments for autoimmune diseases. The BTKs include BTK inhibitor ‘168, currently in a Phase IIb study for multiple sclerosis; rilzabrutinib, an oral BTK inhibitor currently in a Phase III program for moderate to severe pemphigus; and PRN473 topical, a topical agent currently in Phase I trials for immune-mediated diseases.

Sanofi and Principia had previously formed a collaboration in 2017 under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor ‘168 in multiple sclerosis and other central nervous system diseases.

Source: Sanofi

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content